Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
1.005
-0.105 (-9.46%)
At close: May 15, 2026, 4:00 PM EDT
1.020
+0.015 (1.49%)
After-hours: May 15, 2026, 7:03 PM EDT
Immuron Revenue
Immuron had revenue of 4.18M AUD in the half year ending December 31, 2025, with 77.64% growth. This brings the company's revenue in the last twelve months to 7.48M, up 14.30% year-over-year. In the fiscal year ending June 30, 2025, Immuron had annual revenue of 7.29M with 48.63% growth.
Revenue (ttm)
7.48M AUD
Revenue Growth
+14.30%
P/S Ratio
1.32
Revenue / Employee
1,068,145 AUD
Employees
7
Market Cap
6.60M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 7.29M | 2.38M | 48.63% |
| Jun 30, 2024 | 4.90M | 3.10M | 171.67% |
| Jun 30, 2023 | 1.80M | 1.04M | 135.85% |
| Jun 30, 2022 | 765.19K | 619.42K | 424.91% |
| Jun 30, 2021 | 145.78K | -2.37M | -94.21% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Moolec Science | 7.83M |
| Xenetic Biosciences | 3.19M |
| CollPlant Biotechnologies | 2.37M |
| BioAtla | 2.00M |
| XTL Biopharmaceuticals | 968.00K |
| Addex Therapeutics | 218.17K |
| Silo Pharma | 72.10K |
IMRN News
- 23 days ago - Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00 - Accesswire
- 4 weeks ago - Immuron Double Digit 3Q Sales Growth - GlobeNewsWire
- 2 months ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Accesswire
- 2 months ago - Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference - Benzinga
- 4 months ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - Accesswire
- 4 months ago - Immuron Reports Continued Sales Growth - GlobeNewsWire
- 5 months ago - Why Is Immuron Stock (IMRN) Down Today? - TipRanks
- 5 months ago - Immuron (IMRN) Collaborates on Vaccine Research with US Military Institutes - GuruFocus